ReviewCurrent opinion in HIV and AIDS2018
Ethical issues in HIV remission trials.
Review in Current opinion in HIV and AIDS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause in the United States: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.AIDS research and human retroviruses · 2022Trial
- Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.AIDS research and human retroviruses · 2021Trial
- HIV Cure Research: Ethical and Real-World Practical Considerations for Pediatric and Adolescent Populations.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Integrating socio-behavioral, ethics, community, and translational science considerations in HIV cure research.Current opinion in HIV and AIDS · 2025Review
- Lessons Learned in Eliciting Systematic Participant Perspectives in a Combination HIV Cure Research Trial.AIDS research and human retroviruses · 2025Article
- Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium.The lancet. HIV · 2024Review
- Willingness to trade-off years of life for an HIV cure - an experimental exploration of affective forecasting.AIDS research and therapy · 2024Article
- Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States.HIV research & clinical practice · 2024Article
- Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States.HIV research & clinical practice · 2023Article
- A partner protection package for HIV cure-related trials involving analytical treatment interruptions.The Lancet. Infectious diseases · 2023Review
- The ethical case for placebo control in HIV-cure-related studies with ART interruption.Journal of virus eradication · 2022Article
- Community HIV clinicians' perceptions about HIV cure-related research in the Northwestern United States.HIV research & clinical practice · 2022Article
- Attitudes About Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy (ART) Resumption Criteria.AIDS and behavior · 2022Article
- Ethical and practical considerations for cell and gene therapy toward an HIV cure: findings from a qualitative in-depth interview study in the United States.BMC medical ethics · 2022Article
- Ethical considerations for HIV remission clinical research involving participants diagnosed during acute HIV infection.BMC medical ethics · 2021Article
- Considerations for designing and implementing combination HIV cure trials: findings from a qualitative in-depth interview study in the United States.AIDS research and therapy · 2021Article
- Ethics of HIV cure research: an unfinished agenda.BMC medical ethics · 2021Review
- Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?Frontiers in immunology · 2021Review
- "My Death Will Not [Be] in Vain": Testimonials from Last Gift Rapid Research Autopsy Study Participants Living with HIV at the End of Life.AIDS research and human retroviruses · 2020Article
- Cohorts as collections of bodies and communities of persons: insights from the SEARCH010/RV254 research cohort.International health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewSeveral promising experimental pathways exist for long-term control of HIV in the absence of antiretroviral therapy (HIV 'remission') and are now being tested in early clinical studies. These studies can be invasive and pose a host of distinctive risks to participants, as well as to nonparticipants, especially to participants' fetuses, and sexual partners. RECENT
findingsEthical analyses of these studies have mainly focused on the risks to study participants. They recommend, and some investigators implement, procedures to mitigate risks for participants or to offset them with direct, indirect, and nonmedical benefits. They also suggest ways to keep participants' consent highly voluntary and informed. Rarely do ethicists propose keeping the social value of studies high. Of these recommended responses, only the latter, rarer proposals help address the risk to nonparticipants, as would some novel ways to address that risk. SUMMARY: HIV remission studies pose a number of ethical dilemmas. Many current investigative approaches put the participant at significant risk, but well established guidelines exist for mitigating this risk. Ethical issues that are not being fully addressed include risk to nonparticipants and the need to consider the societal value of studies, for example, their prospective impact on the global HIV burden. VIDEO ABSTRACT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.